Total Payments
$399,026
2024 Payments
$175,779
Companies
69
Transactions
1,525
Medicare Patients
4,568
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$168,402 (42.2%)
Research$155,915 (39.1%)
Food & Beverage$33,173 (8.3%)
Consulting$29,453 (7.4%)
Travel$11,934 (3.0%)
Education$148.70 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $155,915 | 8 | 39.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $148,672 | 87 | 37.3% |
| Food and Beverage | $33,173 | 1,367 | 8.3% |
| Consulting Fee | $29,453 | 9 | 7.4% |
| Honoraria | $19,730 | 13 | 4.9% |
| Travel and Lodging | $11,934 | 38 | 3.0% |
| Education | $148.70 | 3 | 0.0% |
Payments by Type
General
$243,111
1,517 transactions
Research
$155,915
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $155,915 | 8 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $84,241 | 170 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $36,214 | 74 | $0 (2022) |
| Amneal Pharmaceuticals LLC | $23,791 | 66 | $0 (2024) |
| ARGENX US, INC. | $22,456 | 40 | $0 (2024) |
| Neurelis, Inc. | $17,598 | 51 | $0 (2024) |
| ABBVIE INC. | $14,478 | 106 | $0 (2024) |
| UCB, Inc. | $7,240 | 131 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $6,752 | 52 | $0 (2022) |
| Eisai Inc. | $5,276 | 12 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $175,779 | 305 | Eli Lilly and Company ($110,925) |
| 2023 | $73,800 | 271 | Neurocrine Biosciences, Inc. ($42,227) |
| 2022 | $52,719 | 239 | Eli Lilly and Company ($24,024) |
| 2021 | $13,358 | 243 | Amneal Pharmaceuticals LLC ($5,146) |
| 2020 | $13,738 | 101 | Eli Lilly and Company ($7,997) |
| 2019 | $24,132 | 164 | Amneal Pharmaceuticals LLC ($9,292) |
| 2018 | $22,689 | 143 | Sunovion Pharmaceuticals Inc. ($13,685) |
| 2017 | $22,812 | 59 | Sunovion Pharmaceuticals Inc. ($22,133) |
All Payment Transactions
1,525 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Neuropsychiatry | ||||||
| 12/18/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Neuropsychiatry | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Neuropsychiatry | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $3.61 | General |
| Category: Neuropsychiatry | ||||||
| 12/13/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $31.62 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $75.14 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Neuropsychiatry | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $1.50 | General |
| Category: Neuropsychiatry | ||||||
| 12/09/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $29.14 | General |
| Category: Central Nervous System | ||||||
| 12/09/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $9.73 | General |
| Category: NEUROLOGY | ||||||
| 12/06/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: EPILEPSY | ||||||
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $28.07 | General |
| Category: Neurology | ||||||
| 12/04/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $11.82 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 12/02/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $5.44 | General |
| Category: NEUROLOGY | ||||||
| 11/26/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Rare Disease | ||||||
| 11/20/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: NEUROLOGY | ||||||
| 11/16/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: Analgesic | ||||||
| 11/13/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 11/13/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 11/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Neuropsychiatry | ||||||
| 11/12/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $98,803 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $16,876 | 2 |
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $15,907 | 2 |
| EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY | Eli Lilly and Company | $12,122 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $7,318 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $4,890 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,043 | 10,975 | $1.6M | $300,697 |
| 2022 | 15 | 990 | 13,863 | $1.7M | $332,640 |
| 2021 | 22 | 1,267 | 14,144 | $1.5M | $292,145 |
| 2020 | 19 | 1,268 | 2,524 | $1.2M | $240,630 |
Total Patients
4,568
Total Services
41,506
Medicare Billing
$1.2M
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 401 | 958 | $754,904 | $138,020 | 18.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 21 | 9,351 | $224,424 | $46,458 | 20.7% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 85 | 85 | $162,690 | $31,107 | 19.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 155 | 155 | $151,280 | $27,455 | 18.1% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 85 | 92 | $93,932 | $20,887 | 22.2% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 53 | 55 | $52,800 | $9,699 | 18.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 82 | $46,084 | $7,949 | 17.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $27,740 | $5,177 | 18.7% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 75 | 96 | $26,880 | $4,908 | 18.3% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 22 | 22 | $24,552 | $4,548 | 18.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 13 | 13 | $20,787 | $3,950 | 19.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 28 | 28 | $2,156 | $540.40 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 317 | 782 | $616,216 | $115,775 | 18.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 20 | 12,300 | $295,200 | $60,067 | 20.3% |
| 95715 | Measurement of brain wave activity with video (veeg), 12-26 hours with intermittent monitoring | Office | 2022 | 17 | 45 | $180,000 | $37,063 | 20.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 73 | 73 | $139,722 | $27,585 | 19.7% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 104 | 118 | $123,163 | $27,389 | 22.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 105 | 105 | $102,480 | $18,642 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 95 | 123 | $69,126 | $11,916 | 17.2% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2022 | 41 | 41 | $45,756 | $8,767 | 19.2% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Office | 2022 | 17 | 46 | $43,056 | $8,466 | 19.7% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 49 | 71 | $19,880 | $3,860 | 19.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $18,980 | $3,683 | 19.4% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2022 | 17 | 17 | $17,000 | $3,506 | 20.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 23 | 30 | $12,990 | $2,550 | 19.6% |
About Dr. Andrew Lerman, M.D
Dr. Andrew Lerman, M.D is a Neurology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2010. The National Provider Identifier (NPI) number assigned to this provider is 1407173974.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Lerman, M.D has received a total of $399,026 in payments from pharmaceutical and medical device companies, with $175,779 received in 2024. These payments were reported across 1,525 transactions from 69 companies. The most common payment nature is "" ($155,915).
As a Medicare-enrolled provider, Lerman has provided services to 4,568 Medicare beneficiaries, totaling 41,506 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Epilepsy
- Location Miami, FL
- Active Since 04/23/2010
- Last Updated 09/02/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1407173974
Products in Payments
- INGREZZA (Drug) $83,879
- APTIOM (Drug) $36,171
- RYTARY (Drug) $23,829
- VYVGART (Drug) $18,760
- VALTOCO (Drug) $17,598
- UBRELVY (Drug) $8,368
- TROKENDI XR (Drug) $6,640
- QULIPTA (Drug) $5,458
- Fycompa (Drug) $5,261
- VYVGART HYTRULO (Drug) $3,672
- ELYXYB - CELECOXIB (Drug) $3,570
- Gocovri (Drug) $3,463
- Rystiggo (Drug) $2,624
- Briviact (Drug) $2,362
- INFINITY (Device) $2,302
- BOTOX (Biological) $1,419
- NURTEC ODT (Drug) $1,380
- Vimpat (Drug) $928.87
- EPIDIOLEX (Drug) $762.31
- ZEMBRACE SYMTOUCH (Drug) $753.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Miami
Dr. Diego Torres-Russotto, Md, MD
Neurology — Payments: $724,144
Neurology $724,144
Flavia Nelson, M.d, M.D
Neurology — Payments: $413,699
Neurology $413,699
Dr. Brad Herskowitz, M.d, M.D
Neurology — Payments: $301,062
Neurology $301,062
Dr. Kottil Rammohan, Md, MD
Neurology — Payments: $297,939
Neurology $297,939
Carlos Ramirez-Calderon, M.d, M.D
Neurology — Payments: $202,041
Neurology $202,041
Alberto Pinzon Ardila, Md, MD
Neurology — Payments: $161,553
Neurology $161,553